2.58

0.39% -0.010

Pre-market: 2.50 -0.08 -3.10%

Nuvation Bio Inc (NUVB)

Overview News Price History Option Chain Discussions Forecast

Nuvation Bio Inc stock is traded at $2.58, with a volume of 3.58M. It is down -0.39% in the last 24 hours and up +3.61% over the past month. Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

Previous Close:

$2.59

Open:

$2.6

24h Volume:

3.58M

Relative Volume:

2.09

Market Cap:

$870.02M

Revenue:

Net Income/Loss:

$-75.80M

P/E Ratio:

-6.2927

EPS:

-0.41

Net Cash Flow:

$-68.07M

1W Performance:

-12.54%

1M Performance:

+3.61%

6M Performance:

-25.86%

1Y Performance:

+91.11%

1-Day Range:

$2.495

$2.615

1-Week Range:

$2.435

$2.98

52-Week Range:

$1.21

$4.1598

Nuvation Bio Inc Stock (NUVB) Company Profile

Name

Nuvation Bio Inc

Sector

Healthcare (1193)

Industry

Biotechnology (683)

Phone

(415) 754-3517

Address

357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO

Employee

203

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

NUVB's Discussions on Twitter

Compare NUVB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NUVB	2.58	870.02M	0	-75.80M	-68.07M	-0.41
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-06-23	Downgrade	Jefferies	Buy → Hold
Aug-02-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
Aug-02-22	Downgrade	BTIG Research	Buy → Neutral
May-04-22	Initiated	H.C. Wainwright	Buy
Oct-15-21	Resumed	BTIG Research	Buy
Apr-06-21	Initiated	RBC Capital Mkts	Outperform
Mar-08-21	Initiated	BMO Capital Markets	Outperform
Mar-08-21	Initiated	BTIG Research	Buy
Mar-08-21	Initiated	Cowen	Outperform
Mar-08-21	Initiated	Jefferies	Buy
Mar-08-21	Initiated	Wedbush	Outperform

View All

Nuvation Bio Inc Stock (NUVB) Latest News

Nov 20, 2024

Nuvation Bio's SWOT analysis: taletrectinib drives stock potential amid challenges - Investing.com India

Nov 13, 2024

FMR LLC Bolsters Stake in Nuvation Bio Inc - GuruFocus.com

Nov 13, 2024

Nov 12, 2024

Nuvation Bio to Present at the Jefferies London Healthcare Conference - Business Wire

Nov 12, 2024

Nov 11, 2024

What is Wedbush's Estimate for Nuvation Bio FY2024 Earnings? - MarketBeat

Nov 11, 2024

Nov 08, 2024

Nuvation Bio (NYSE:NUVB) Shares Gap Up After Analyst Upgrade - MarketBeat

Nov 08, 2024

Nuvation Bio’s Global Challenges: Navigating Risks in China Amid Geopolitical Tensions - TipRanks

Nov 08, 2024

Nov 07, 2024

Royal Bank of Canada Increases Nuvation Bio (NYSE:NUVB) Price Target to $6.00 - MarketBeat

Nov 07, 2024

Nuvation Bio reports Q3 EPS (15c, consensus (13c) - TipRanks

Nov 07, 2024

Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace

Nov 07, 2024

Nov 06, 2024